# Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer

> **NCT01759238** · PHASE2 · TERMINATED · sponsor: **Universitätsklinikum Hamburg-Eppendorf** · enrollment: 1 (actual)

## Conditions studied

- Colorectal Cancer
- Metastases

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Bevacizumab
- **RADIATION:** Radiotherapy

## Key facts

- **NCT ID:** NCT01759238
- **Lead sponsor:** Universitätsklinikum Hamburg-Eppendorf
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-05
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** unexpectedly slow recruitment
- **Last updated:** 2022-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01759238

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01759238, "Chemoradiotherapy for Patients With Oligometastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01759238. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*